Positive data narrow odds on Veracyte’s lung cancer Dx bet
This article was originally published in Clinica
Newly published data supporting Veracyte’s Percepta bronchial genomic classifier lung cancer test might help position it as a go-to non-invasive assay, just as millions more patients are becoming eligible for routine lung-cancer screening with computer tomography.
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.